Format

Send to

Choose Destination
Drug Discov Today. 2012 Feb;17(3-4):160-6. doi: 10.1016/j.drudis.2011.09.015. Epub 2011 Sep 29.

Liposomal drug formulations in cancer therapy: 15 years along the road.

Author information

1
Department of Medical Oncology, Leiden University Medical Center, The Netherlands.

Abstract

Liposomes as pharmaceutical drug carriers were developed to increase antitumour efficacy and decrease drug toxicity. Doxorubicin HCl liposomal injection was the first liposomal encapsulated anticancer drug to receive clinical approval. To date, virtually all traditional anticancer drugs have been encapsulated in liposomes. The majority of clinical studies only support the concept of a decreased toxicity and better tolerability of the liposomal anticancer drug. Although liposomal anticancer drugs have grown to maturity in several indications and are now in widespread further development programmes using their theoretical advantages to fulfil the high expectations, further studies are warranted--including the development of novel liposomal formulations.

PMID:
21983329
DOI:
10.1016/j.drudis.2011.09.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center